Log In

 

Company Name : Ferring Pharmaceuticals

Tuesday, October 10, 2017 8:05PM IST (2:35PM GMT)

(BW)(FERRING-PHARMACEUTICALS)

Ferring Strengthens Growth Hormone Franchise Zomacton® Through Acquisition of ZomaJet™ Needle-Free Injector Device


Ferring enters agreement with Antares Pharma Inc. for worldwide rights to ZomaJet™ needle-free injector device; ZomaJet is used to deliver Ferring’s Zomacton® (somatropin), indicated to treat Growth Hormone Deficiency in children and Turner Syndrome in girls; ZomaJet helps increase adherence to treatment through its needle-free feature and the ability to self-administer 1,2,3


Saint-Prex, Switzerland

Ferring Pharmaceuticals announced today that it has entered into a definitive agreement with Antares Pharma, Inc. to acquire the worldwide rights for the ZomaJet™ needle-free auto injector device.

 

This transaction is subject to customary closing conditions. Antares will continue to manufacture and supply the ZomaJet device until completion of existing supply arrangements, expected by the end of 2018.

 

ZomaJet is used to deliver Ferring’s Zomacton® (somatropin), a treatment indicated for the treatment of Growth Hormone Deficiency (GHD) in children and Turner Syndrome in girls.

 

“Through the acquisition of ZomaJet, we are consolidating our Zomacton franchise and commitment to improving quality of life and care for children with growth disorders,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals. “ZomaJet addresses the common problem of needle fear in children, lowering the burden for patients and care givers and leading to better adherence to treatment.”

 

Ferring is a recognised speciality player in endocrinology, with a commitment to addressing the unmet medical needs of patients with childhood growth disorders including GHD and Turner Syndrome.

 

About ZomaJet™

 

ZomaJet devices are needle-free delivery systems for the administration of Zomacton® (somatropin) human growth hormone (hGH).

 

About Zomacton®

 

Zomacton® (somatropin) is a synthetic human growth hormone (hGH) produced by recombinant DNA technology. The main use for the product is to treat Growth Hormone Deficiency (GHD) in children and Turner Syndrome in girls.

 

About Ferring Pharmaceuticals:

 

Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. A leader in reproductive and maternal health, Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative treatments to help mothers and babies, from conception to birth. The company also identifies, develops and markets innovative products in the areas of urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. For further information on Ferring or its products, visit www.ferring.com.

 

Ferring is on Twitter. Follow us @FerringNews at http://twitter.com/FerringNews

 

References

 

1 Haverkamp F. & Gasteyger G. Journal of Medical Economics 2011; 14(4): 448-457

 

2 Wickramasuriya B.P. et al, Horm Res 2006; 65(1): 18-22

 

3 Main K.M. et al, Acta Paediatr 1995; 84(3): 331-334

 

 

 

 


Click here for Media Contact Details
CONTACTS :

Ferring Corporate Communications Team:
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
or
Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com


More News from Ferring Pharmaceuticals

28/11/2017 1:59AM

Ferring Receives Swiss Approval For Rekovelle®, The First Personalised Fertility Treatment Using an Approved Dosing Algorithm

Ferring Pharmaceuticals announced today that Swissmedic has approved Rekovelle® (follitropin delta) for use in controlled stimulation for induction of the development of multiple follicles in women undergoing ...

03/10/2017 9:10AM

Ferring Appoints Klaus Dugi as Executive Vice President and Chief Medical Officer

Ferring Pharmaceuticals announced that Professor Klaus Dugi has been appointed Executive Vice President and Chief Medical Officer, effective immediately.   He will be responsible for Global Medical Affairs, ...

06/07/2017 11:50AM

Ferring Appoints Lars Peter Brunse to Executive Board

Ferring Pharmaceuticals announced today that Lars Peter Brunse has been appointed Executive Vice President and Chief Production Officer, and made a member of the Ferring Executive Board, effective ...

Similar News

09/12/2017 1:30PM Image

मित्‍सुई केमिकल्‍स एग्रो, इंक. (एमसीएजी) और बीएएसएफ ने आइआरएसी के मौलिक मोड ऑफ ऐक्‍शन के साथ नये कीटनाशक के लिए व्‍यावसायिक अनुबंध पर हस्‍ताक्षर किये

मित्‍सुई केमिकल्‍स एग्रो, इंक.(एमसीएजी) और बीएएसएफ एसई ने  ब्रोफ्‍लैनिलाइड के व्‍यावसायिकरण के लिए दीर्घकालिक अनुबंध पर हस्‍ताक्षर करने की घोषणा की है। यह फसलों को खाने वाले कीटों एवं गैर-फसली ...

No Image

09/12/2017 11:45AM

Bertin and Zymo Research Announce New Collaboration

Zymo Research Corp. and Bertin announce a collaboration that ensures the sample lysis step in the microbiome workflow is complete and unbiased. An application note is available describing the materials, procedure and ...